Century Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPSC research report →
Range $2 – $2
Price Chart
About the company
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy.
- CEO
- Brent Pfeiffenberger
- IPO
- 2021
- Employees
- 78
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on IPSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $182.66M
- P/E
- -2.03
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.87
- EV/EBITDA
- -1.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.76%
- ROIC
- -43.66%
Latest fiscal year · YoY change
- Revenue
- $109.16M+1556.8%
- Gross Profit
- $96.06M+1357.9%
- Op Income
- $-15,040,000
- Net Income
- $-9,580,000+92.4%
- EPS
- $-0.11+93.2%
- OCF Growth
- +5.7%
- FCF Growth
- +5.0%
- 52W High
- $3.04
- 52W Low
- $0.43
- 50D MA
- $2.18
- 200D MA
- $1.85
- Beta
- 1.60
- RSI (14)
- 53
- Avg Volume
- 1.22M
No earnings-call transcripts are available for IPSC yet.
- Free Float
- 56.2%
- Shares Outstanding
- 86.57M
- Float Shares
- 48.65M
of shares held by institutions
46 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.10M | 0 |
| Two Sigma Advisers, LP | 1.27M | ▲ 410.10K |
| Point72 Asia (Singapore) Pte. Ltd. | 17.86K | ▼ 19.02K |
| Point72 (Difc) Ltd | 1.06K | ▼ 685 |
Held by 84 ETFs
Biggest fund positions in IPSC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Pfeiffenberger Brent | other | 31,172 |
| Aug 3, 26 | Carr Douglas | sell | 275 |
| Jun 12, 26 | Russotti Gregory | sell | 2,584 |
| Jun 12, 26 | Carr Douglas | sell | 1,654 |
| Jun 11, 26 | Pfeiffenberger Brent | other | 13,849 |
| Jun 11, 26 | Cowan Chad | other | 358 |
| Jun 11, 26 | Riva Alessandro | other | 74,000 |
| Jun 11, 26 | Quimi Daphne | other | 74,000 |
| Jun 11, 26 | Murphy Martin Patrick | other | 74,000 |
| Jun 11, 26 | Lee Han Myung | other | 74,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IPSC coverage
Recent articles, reports, and earnings notes.
No research on IPSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPSC report →Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
globenewswire.com · Aug 12
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
businesswire.com · Jul 23
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
globenewswire.com · Jul 9
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
globenewswire.com · Jun 8
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
globenewswire.com · Jun 8
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
globenewswire.com · May 14
Century Therapeutics Reports First Quarter Financial Results and Business Updates
globenewswire.com · May 13
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
globenewswire.com · Apr 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.